Literature DB >> 11414194

Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice.

G Stüben1, O Thews, C Pöttgen, K Knühmann, P Vaupel, M Stuschke.   

Abstract

PURPOSE: The effect of recombinant human erythropoietin (Epo) on the radiosensitivity of human tumour xenografts growing in anaemic nude mice was studied. METHODS AND MATERIALS: Anaemia was induced by total body irradiation (TBI) of mice prior to tumour transplantation. The development of anaemia was prevented by Epo (1000 U/kg s.c.) given 3 times weekly starting 2 weeks prior to TBI (5 Gy). Epo treatment did not influence the growth rate of the tumours, which were transplanted into the subcutis of the hind leg of mice. Thirteen days after TBI (tumour volume of approx. 40 mm3), a single-dose irradiation (12 Gy) of the tumour was performed resulting in a growth delay with subsequent regrowth of the tumours.
RESULTS: In Epo-treated animals the tumour growth delay was significantly longer compared to anaemic mice. However, the radiosensitivity of tumours in non-anaemic animals' (non-Epo-treated) tumours could not fully be restored.
CONCLUSION: These data give evidence for restored radiosensitivity after correction of anaemia with Epo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414194     DOI: 10.1007/s004320000215

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

Review 1.  [The aftercare principle for metastasizing prostate cancer. Few diagnostics, much support].

Authors:  K Heine; J M Wolff
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 2.  Indications for and complications of transfusion and the management of gynecologic malignancies.

Authors:  Paulina Cybulska; Cheryl Goss; William P Tew; Rekha Parameswaran; Yukio Sonoda
Journal:  Gynecol Oncol       Date:  2017-05-18       Impact factor: 5.482

3.  Pleiotrophic actions of erythropoietin.

Authors:  Laurie Feldman; Arthur J Sytkowski
Journal:  Environ Health Prev Med       Date:  2003-01       Impact factor: 3.674

Review 4.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

Review 5.  The clinical value of erythropoietin in patients with cancer.

Authors:  Ulrich Dührsen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

Authors:  Mitchell Machtay; Jennifer Moughan; Andrew Trotti; Adam S Garden; Randal S Weber; Jay S Cooper; Arlene Forastiere; K Kian Ang
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

7.  Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Authors:  Makito Miyake; Steve Goodison; Adrienne Lawton; Ge Zhang; Evan Gomes-Giacoia; Charles J Rosser
Journal:  J Hematol Oncol       Date:  2013-09-03       Impact factor: 17.388

8.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

9.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

10.  Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.

Authors:  Kruttika Bhat; Kiri Sandler; Sara Duhachek-Muggy; Claudia Alli; Fei Cheng; Neda A Moatamed; Clara E Magyar; Lin Du; Gang Li; Susan McCloskey; Erina Vlashi; Frank Pajonk
Journal:  Breast Cancer Res       Date:  2019-01-30       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.